Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
436 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 436 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial… | Early Phase 1 | withdrawn | Oct 23, 2013 | University of Arkansas | Study has been open for 8 years with no enrollment. Procedures in 2013 protocol are outdated.… | Enrollment / accrual |
| NCT03875859 | Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma… | Phase 2 | terminated | Mar 15, 2019 | Kavita Sarin | The available study medication reached expiry (logistics). | Other (stated, no rule matched) |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in…(ADHERE) | Phase 3 | withdrawn | Sep 17, 2018 | European Organisation for Research and Treatment of Cancer - EORTC | Company withdrew interest | Sponsor / business decision |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | Phase 1 | withdrawn | Jun 27, 2007 | University of Maryland, Baltimore | major amendments in progress | Other (stated, no rule matched) |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated…(Pelican) | Phase 1 | withdrawn | Dec 12, 2018 | Turnstone Biologics, Corp. | insufficient suitable drug supply | Drug supply |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced… | Phase 2 | suspended | Sep 10, 2019 | Zhejiang Cancer Hospital | combination arm delevelped significant poor prognosis | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck… | Phase 1 / Phase 2 | terminated | May 18, 2012 | Novartis Pharmaceuticals | early termination due to Sponsor decision (slow recruitment) | Enrollment / accrual |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Washington University School of Medicine | Provider of drug decided to discontinue study. | Other (stated, no rule matched) |
| NCT00011492 | Patient Evaluation for Head and Neck Surgery Branch Studies | — | terminated | Feb 23, 2001 | National Institute on Deafness and Other Communication Disorders (NIDCD) | Closed by Sponsor/Data Safety monitoring Board/IRB | Safety / toxicity |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care… | Phase 2 | withdrawn | Feb 13, 2020 | SWOG Cancer Research Network | The pharmaceutical company sold the compound and pulled out. | Sponsor / business decision |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT03276819 | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML…(UMBRELLA) | N/A | terminated | Sep 8, 2017 | Centre Leon Berard | Early termination of the study, since July 31, 2020 for insufficient recruitment | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | Phase 2 | withdrawn | Sep 17, 2019 | Beijing Konruns Pharmaceutical Co., Ltd. | The study was terminated voluntarily by the sponsor due to changes in clinical development strategy. | Sponsor / business decision |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | Phase 1 | terminated | Jun 8, 2015 | University of Texas Southwestern Medical Center | unexpected toxicities | Safety / toxicity |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil… | Phase 2 | terminated | Dec 23, 2013 | Nang Kuang Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03206125 | NCI UNC Project ESCC | — | terminated | Jul 2, 2017 | National Cancer Institute (NCI) | determined not to be human subjects research | Other (stated, no rule matched) |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the… | Phase 2 | terminated | Sep 1, 2010 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the…(AGMT_HNO_PN) | Phase 3 | terminated | Sep 11, 2014 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Study stopped due to low recruitment | Enrollment / accrual |
| NCT02541903 | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Sep 4, 2015 | University of Alabama at Birmingham | poor overall accrual | Enrollment / accrual |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous… | Phase 1 | withdrawn | Jun 28, 2011 | Mayo Clinic | lack of access to study drug | Other (stated, no rule matched) |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT03463161 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed…(ORKA) | Phase 2 | terminated | Mar 13, 2018 | University of Chicago | Study stopped early due to investigator conflict of interest. | Investigator |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor… | Phase 1 | withdrawn | Feb 19, 2016 | Yale University | The study was stopped due to lack of funding. | Funding |
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | Phase 1 | terminated | Apr 29, 2015 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Decided by the investigator due to the difficulties to recruit | Investigator |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | — | terminated | Oct 26, 2017 | Philip Schaner | The research team is exploring device optimization | Other (stated, no rule matched) |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod… | Phase 1 | terminated | Apr 28, 2014 | Celgene | not stated | Not stated |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | Phase 2 | terminated | Dec 6, 2006 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Too frequent grade 3-4 toxicities | Safety / toxicity |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or… | Phase 1 | withdrawn | Jul 2, 2018 | Emory University | funding and drug were withdrawn | Funding |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced… | N/A | withdrawn | Aug 2, 2018 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle… | Phase 2 | terminated | Jun 5, 2012 | Fox Chase Cancer Center | Extreme Toxicity | Safety / toxicity |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With… | Phase 3 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | Study drug no longer available resulting in lack of study drug for participants. | Other (stated, no rule matched) |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | Phase 1 / Phase 2 | terminated | Mar 21, 2016 | PrECOG, LLC. | Company discontinued further development of study drug for this indication | Sponsor / business decision |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of… | Phase 1 | withdrawn | Aug 29, 2018 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT01498757 | Genome-wide Association Study | — | withdrawn | Dec 23, 2011 | Samsung Medical Center | Registration poor | Other (stated, no rule matched) |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type…(E-DIS) | Phase 2 | terminated | Nov 25, 2010 | Centre Oscar Lambret | not stated | Not stated |
| NCT03388931 | Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or… | Phase 4 | withdrawn | Jan 3, 2018 | University of Florida | lack of subject enrollment | Enrollment / accrual |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell… | Phase 2 | withdrawn | Oct 30, 2017 | University of Chicago | Site decided not to move forward with trial. Study never opened to enrollment. | Enrollment / accrual |
| NCT00507702 | Identification of Key Blood Molecular Markers for Immunotherapy | — | terminated | Jul 26, 2007 | Stanford University | Improving assay methods | Other (stated, no rule matched) |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | Phase 2 | terminated | Mar 11, 2016 | University of Chicago | Study stopped due to poor enrollment. | Enrollment / accrual |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH…(PICH) | Phase 1 / Phase 2 | withdrawn | Apr 14, 2017 | Centre Antoine Lacassagne | MSD would not able to support the study's continuation after protocol modifications required by… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 31, 2021source: clinicaltrials